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Abstract
The dynamics of Plasmodium vivax infection is characterized by reactivation of hypnozoites
at varying time intervals. The relative contribution of new P. vivax infection and reactivation
of dormant liver stage hypnozoites to initiation of blood stage infection is unclear. In this
study, we investigate the contribution of new inoculations of P. vivax sporozoites to primary
infection versus reactivation of hypnozoites by modeling the dynamics of P. vivax infection
in Thailand in patients receiving treatment for either blood stage infection alone (chloro-
quine), or the blood and liver stages of infection (chloroquine + primaquine). In addition, we
also analysed rates of infection in a study in Papua New Guinea (PNG) where patients were
treated with either artesunate, or artesunate + primaquine. Our results show that up to 96%
of the P. vivax infection is due to hypnozoite reactivation in individuals living in endemic
areas in Thailand. Similar analysis revealed the around 70% of infections in the PNG cohort
were due to hypnozoite reactivation. We show how the age of the cohort, primaquine drug
failure, and seasonality may affect estimates of the ratio of primary P. vivax infection to hyp-
nozoite reactivation. Modeling of P. vivax primary infection and hypnozoite reactivation pro-
vides important insights into infection dynamics, and suggests that 90–96% of blood stage
infections arise from hypnozoite reactivation. Major differences in infection kinetics between
Thailand and PNG suggest the likelihood of drug failure in PNG.
Author Summary
Plasmodium vivax is one of two major parasite species causing human disease. This para-
site can lie dormant in the liver as a hypnozoite, before later reactivating to cause blood-
stage infection. Treatment to eliminate the dormant hypnozoite stage relies mostly on a
single drug—primaquine. Understanding the rate of primary infection versus hypnozoite
reactivation is important to understanding primaquine efficacy and drug resistance, as
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well as the development of new drugs targeting hypnozoites. Here we use mathematical
modeling to analyse data from two clinical cohorts and show that up to 96% of infections
may be caused by hypnozoite reactivation. We also use modeling to understand the impact
of drug resistance, seasonal infection and subject age.
Introduction
Plasmodium vivax is one of the major agents of malaria infection, with around 2.5 billion peo-
ple living in areas at risk of infection, and more than 70 million estimated annual infections
[1–3]. P. vivax is generally less pathogenic than Plasmodium falciparum infection due to the
absence of sequestration and cytoadherence, and all blood-stage forms can be detected in pe-
ripheral circulation[4]. P. vivax also differs due to the development of dormant hypnozoite
forms in the liver, which serve as reservoir of infection after the clearance or treatment of the
acute blood stage of infection. P. vivax shows a preference for reticulocytes as its host cell in the
blood-stage of its life-cycle [5].
The potential for reactivation of dormant hypnozoites creates a number of difficulties in un-
derstanding the transmission dynamics of P. vivax infection[6], however the majority of diag-
nosed infections are thought to be due to hypnozoite reactivation rather than new primary
infection [7–9]. After treatment to eliminate blood stage infection, new infections may occur as
a result of recrudescence (failure of treatment of the blood stage), hypnozoite reactivation, or
new primary infection. Although comparison of P. vivax genotypes may be useful in distin-
guishing recrudescence of the blood stage parasites after treatment, it is not always useful in
differentiating reactivation of a dormant hypnozoite from new primary infection [10–12]. This
is because the parasites causing relapses are often genetically different from those observed in
the most recent blood-stage infection, so it is not possible to differentiate reactivation from
new primary infection using genotyping[13, 14]. Therefore, it is difficult to know the propor-
tion of blood stage infections due to hypnozoite reactivation versus new primary infection by
P. vivax.
In this study, we aim to apply mathematical modeling to quantify the relative contribution
of new primary infection, and infection initiated due to the reactivation of dormant liver stage
hypnozoites. We analyse data from two published prospective studies where individuals were
treated to eliminate blood-stage infection, and a subset were treated with primaquine, a li-
censed radical treatment for hypnozoites, to eliminate preexisting hypnozoites [15, 16]. By
comparing the rate of observed blood stage infection in the two groups, we can estimate the
contribution of primary infection versus hypnozoite reactivation in P. vivax infection.
Materials and Methods
Thailand study data
The field study data were from a published prospective study with recruitment from July 1995
to July 1996, on 342 individuals of different ages (68% (258)<15 years of age) living on the
western border of Thailand where P. vivax is endemic[9]. Individuals with asexual forms of P.
vivax on a blood smear were enrolled, treated with chloroquine (25mg base/kg over 3 days)
and followed up until presentation of pure or mixed P. vivax blood stage infection. Individuals
with reappearance of pure P. vivax infection were retreated with either chloroquine only (70 in-
dividuals with mean age (range) 12 (1–50)) or chloroquine and primaquine (0.25 mg/kg daily
for 14 days, 43 individuals with mean age (range) 13 (5–43)), and were followed up by
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microscopy until detection of P. vivax blood stage parasites. Each dose of chloroquine was su-
pervised and the patient observed for 1 hour after dosing. The criteria for enrollment and
method of detection and quantification of P. vivax parasites in the blood smears are detailed
elsewhere[9]. From the fact that primaquine can kill liver stage hypnozoites[15, 16] we classi-
fied the data in two groups: individuals retreated with chloroquine+primaquine (CQ+PQ)
group and individuals retreated with chloroquine only (CQ only) group.
Papua New Guinea (PNG) study
We also analysed published data on a treatment-time-to-infection study in PNG [8]. In this
study, the contribution of relapse to the risk P. vivax infection and disease was studied in 433
PNG children 1–5 years of age. Children were randomized into one of three groups: (1) artesu-
nate (4mg/kg/d for 7 days) plus primaquine (0.5 mg/kg/d for 14 days), 149 individuals, (2)
artesunate only (4 mg/kg/d for 7 days), 150 individuals or (3) no treatment (control), 150 indi-
viduals, and were followed up for infection and the presence of febrile illness. Every dose of
treatment was administered as direct observed therapy. The criteria for enrollment, method of
randomization, treatment procedures and method for the detection and quantification of P.
vivax parasites in the blood smears were detailed in the original publication [8]. For our analy-
sis we extracted data on infection rates from Fig. 2 of Betuela et al [8], using Grafula 3.0
(Knowledge Probe Inc, Aurora)to extract data on cumulative proportion of infections detected
by light microscopy. The data was classified into two groups; those receiving artesunate+pri-
maquine (AS+PQ group), and artesunate only (AS only) group).
Modeling dynamics of P. vivax infection
The dynamics of P. vivax infection are characterized by both primary infection and reactiva-
tion. For individuals living in P. vivax endemic regions both primary infection and activation
of hypnozoites occur throughout the year. For modelling purposes we will label the two groups
of subjects as i) the B+H group, comprising individuals who received drugs against both blood
stage parasites and hypnozoites and ii) the B group, comprising individuals who received drugs
against blood stage parasites only. We initially assume 100% drug efficacy against both the
blood and liver stage parasites. Thus for individuals receiving in the B+H group, all observed
infection is due to new primary infection. For individuals in the B group, infections can arise ei-
ther from new primary infection, or from reactivation of hypnozoites. Thus, we can model the
time to first P. vivax infection after treatment, and fit this to the ‘survival curve’ of time to de-
tection of P. vivax infection after treatment. The proportion of treated individuals in the B+H
group remaining uninfected at a given time t is indicated as (SB+H(t)) and follows the equation:
SBþHðtÞ ¼
1; t  d1




and the proportion of treated individuals in the B group remaining uninfected at time t is indi-
cated as (SB(t)) and follows the equation
SBðtÞ ¼
1; t  d2
ekð1þcÞðtd2Þ; t > d2
(
ð2Þ
Here k is the rate of initiation of new primary infections, c is the relapse to reinfection ratio and
d1 and d2 are delays to detection of blood stage P. vivax parasites in the groups respectively.
Fig. 1A and 1B show the schematic representation of Equation (1) and (2) where individual
Dynamics of P. vivax Infection and Reactivation
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Fig 1. Schematic of primaquine treated P.vivax infection in the study population. (A) shows the effect of
successful liver and blood stage treatment of individuals in a P.vivax endemic region over time. Individuals
become infected due to primary infection at the rate k, as the hypnozoite reservoir has been successfully
cleared. In panel B, individuals are treated for blood stage parasites only. This results in blood stage infection
from hypnozoite reactivation at the rate kc, and new infectious mosquito bites at the rate k. Panel C shows a
scenario where hypnozoites and blood stage parasites are successfully cleared in some proportion of the
population (top half of panel), and this population experiences new primary infections only (at rate k). The
remaining proportion of the population has primaquine resistance, and thus retains their reservoir of
hypnozoites. These resistant individuals will become infected at the rate k for primary infection and kc for
hypnozoite reactivation.
doi:10.1371/journal.pntd.0003595.g001
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received treatments for either both blood stage and liver stage parasites or blood stage
parasites only.
Modeling dynamics of P. vivax infection with primaquine resistance
The modeling above assumes that all primaquine is completely effective in all individuals.
However, if primaquine fails to kill hypnozoites from a proportion of strains, or in a proportion
of individuals, then we expect altered dynamics. If primaquine kills only a fraction of hypno-
zoites, then the equation for SB+H(t) becomes:
sBþHðtÞ ¼
1; t  d1
ekð1þRcÞðtd2Þ; t > d1
(
ð3Þ
Where R is the fraction of hypnozoites that are resistant to primaquine. We note that in our
study we cannot differentiate between this and Equation (2) with a different c.
If primaquine only kills hypnozoites in a subset of individuals, then primaquine resistant in-
dividuals will behave as if they have not received primaquine. Thus, if primaquine is only effec-
tive in a proportion of individuals, the rate of infection of individuals in the B+H group will be;
sBþHðtÞ ¼
1; t  d1




where P is the proportion of individuals in whom primaquine is effective. The dynamics is il-
lustrated in Fig. 1C. Equations (1), (2) and (4) were fit to the data using the lsqnonlin function
Fig 2. Schematic of P. vivax infection. The dynamics of P. vivax infection starts from a successful mosquito
inoculation. We denote the rate of successful mosquito inoculation asM. Each successful mosquito
inoculation successfully infects on average S liver cells (ie: leads to S blood stage infections). A fraction f of
infected liver cells proceeds to early infection, leaving a fraction (1-f) as hypnozoites to later reactivate. The
rate of new blood stage infections is thusMS, which is equivalent to rate of initiation of new infection observed
in individuals treated with either chloroquine plus primaquine, or artesunate plus primaquine (k in Equations
1–4). Hypnozoites (H) are formed at a rate (1-f)MS and reactivate at rate aH. The total rate of blood stage
infection (from new infection plus hypnozoites) settles toMS (ie: the rate of blood stage infection is the same
as the rate of successful infection of new liver cells in steady state). The total rate of new blood stage infection
MS is equivalent to the infection rate observed in individuals treated with chloroquine or artesunate alone ((k
(1+c)) in Equations 1–4).
doi:10.1371/journal.pntd.0003595.g002
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in MATLAB R2012 (Release M (2012) The MathWorks Inc, Natick, MA, USA), which uses a
nonlinear least-squares method, to understand the contribution of hypnozoites reactivation to
the dynamics of P. vivax infection.
Modeling the dynamics of P.vivax hypnozoite reactivation
To understand the different contributions of primary infection and reactivation, we need to
understand how the force of infection from primary infection and hypnozoite reactivation
evolve over time / with exposure starting with a naïve host. If we consider a fixed rate of infec-
tious mosquito inoculation (M), and that each inoculation infects a number of liver cells (S)
that will eventually go on to produce a blood stage infection, then the total rate of successful in-
fection of liver cells is simplyMS. Assuming that the time spent in the liver stage is negligible
for primary infection, the rate of new primary infections (Ip) is simply the overall rate of infec-
tion of liver cellsMSmultiplied by the fraction of liver cell infections that result in primary in-
fection (f):
IP ¼ fMS ð5Þ
We note that fMS is equivalent to k in Equations 1–4. Importantly, the rate of successful infec-
tion of liver cells may not be the same as the rate of successful mosquito inoculation (as one
successful inoculation may infect one or more liver cells, see Fig. 1). Moreover, the definition of
successful infection of a liver cell is not simply that a cell becomes infected, but that the infected
cell gives rise to a blood stage infection at some stage (either immediately or with some delay).
If we consider an individual that starts with no hypnozoites (for example a neonate, or
someone successfully treated with primaquine), the number of hypnozoites and rate of infec-
tion from hypnozoite reactivation (IH) evolves over time as hypnozoites accumulate upon re-
peated infection. Hypnozoites accumulate dependent on the rate of infection of liver cells
(MS), and the fraction of liver cells that become hypnozoites (1-f). The dynamical equation for
the number of hypnozoites (H) over time is
dH
dt
¼ ð1 f ÞMS aH ð6Þ
where a is the reactivation rate of hypnozoites. We note that this assumes that hypnozoites
never infect more than a tiny proportion of total liver cells. The rate of infection due to hypno-
zoite reactivation is then simply:
IH ¼ aH ð7Þ
The solution of Equations (6) and (7) is
IH ¼ ð1 f ÞMSð1 eatÞ þ aH0eat ð8Þ
whereH0 is the initial number of hypnozoites. At steady state, the rate of infection from hypno-
zoites (IH) in Equations 7 and 8 is equivalent to kc in Equations 2 and 4. Similarly, the total rate
of new blood stage infections at steady state is simplyMS (the rate of successful infection of
liver cells). Fig. 2 illustrates the mechanisms of infection and the relationship between parame-
ters in Equations 1–4, and 5–7.
Modeling the effects of seasonality
Plasmodium vivax infection often follows a seasonal pattern, with higher infection in the wet
season[17, 18]. To understand the role of fluctuations in the force of infection and the effect of
seasonality, we modified Equation (6) by allowing the rate of infectious mosquito inoculation
Dynamics of P. vivax Infection and Reactivation
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to vary seasonally;
M ¼ Msð1þMf cosð2pt=365ÞÞ ð9Þ
whereMs is the mean rate of infectious mosquito inoculation andMf is a parameter for the de-
gree of seasonal fluctuation. The periodicities of these functions are such they divide the season
into dry and wet seasons. We examine the effect of seasonality and EIR on the contribution of
primary infection to reactivation by numerical simulations of Equations (5) and (6) with sea-
sonality terms included.
Results
The ratio of primary P.vivax infection to hypnozoite reactivation in
Thailand
We first estimated using Equation (1) the rate of infection in individuals receiving chloroquine
plus primaquine treatment in Thailand, in whom all infections are assumed to be due to new
primary infection. Assuming a constant force of infection, we found that a rate of infection of
approximately 0.0017 per day (equating to an average time to primary infection of 588 days)
provided the best fit to the data (Fig. 3A). We next estimated the rate of infection and reactiva-
tion occurring in the individuals that received chloroquine alone using Equation (2), where in-
fection can arise due to both new primary infection as well as hypnozoite reactivation. In this
case, we observed the rate of 0.043 infections per day (equivalent to an average of 23 days to in-
fection). Since the individuals receiving chloroquine alone experience both primary infection
and reactivation from hypnozoites, we can subtract the rate of primary infection (estimated in
the CQ + PQ group) to estimate the rate of hypnozoite reactivation. Thus, we estimate a rate of
hypnozoite reactivation of 0.0413 per day (equivalent to a hypnozoite reactivation every 24
days). There was no evidence for a difference in the delays from treatment to first detection in
the CQ+PQ group and the CQ group (p = 0.8563, F-test).
The relative rates of new primary infection and hypnozoite reactivation estimated in this
data suggest that approximately 4% of infection events in individuals receiving chloroquine oc-
curred due to primary infection, and approximately 96% of infection events occurred due to
hypnozoite reactivation. This implies a ratio of primary infection to hypnozoite reactivation of
approximately 1 to 24.
Hynozoite reactivation reflects hypnozoite production rate
Once hypnozoites are laid down, they will reactivate at some later time either spontaneously,
or following some form of stimulation (such as fever or concurrent infection). So, for a single
bite we might imagine there is some average time to reactivation, and a distribution in the
probability of reactivation with time. The delay between initial inoculation and subsequent
hypnozoite reactivation is highly variable[19, 20]. However, even in the absence of knowing
the precise schedule of reactivation of individual hypnozoites, we can still understand the dy-
namics of reactivation in an endemic setting. That is, in an endemic setting we do not observe
reactivation from a single inoculation, but in fact from a long series of past inoculations. We
have a probability of reactivation from an inoculation 6 months ago, which is dependent on
the rate of inoculation six months ago, the proportion of hypnozoites surviving 6 months, and
the rate of reactivation of 6 month old hypnozoites. The same is true for hypnozoites inoculat-
ed a month ago, or a year ago. In this circumstance if we have a constant rate of inoculation for
individuals of a particular age group who have been exposed to Pv infections for a sufficient
time to reach ‘steady state’ of infection, where each the average rate of reactivation of
Dynamics of P. vivax Infection and Reactivation
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Fig 3. The rate of primary infection versus hypnozoite reactivation in Thailand. (A) Modelling was performed to estimate the rate of blood stage
infection in individuals treated with chloroquine (blue), or chloroquine + Primaquine (black). The actual rate of inoculation of new infections cannot be directly
estimated from this data. Panels B-D show several possible rates if infectious inoculation (green dashed line) that could explain the data. (B), The minimal
rate of inoculation occurs if every new inoculation were observed as a primary infection. In this case, the infectious inoculation rate equals the rate of infection
in the CQ+PQ group (a new inoculation every 588 days), and each inoculation must lay down 24 hypnozoites that later reactivate. (C), The maximal rate of
infectious inoculation would be if each inoculation lead to either one primary infection, or one later reactivation. In this case, only 4% of inoculations would
present as primary infections, and the rest lay down one hypnozoites that later reactivates. (D), The most likely infectious inoculation rate appears an
intermediate between these extremes (of (B) and (C)), in which only a portion of inoculations leads to primary infection, and each inoculation lays down
several hypnozoites. In panel D the green line illustrates a rate at infectious inoculation where20% of inoculations leads to primary infection, and each
inoculation lays down5 hypnozoites.
doi:10.1371/journal.pntd.0003595.g003
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hypnozoites reflects the rate at which they were laid down (from Equation (6), when the num-
ber of hypnozoites is constant dH
dt
¼ 0 , then the rate of hypnozoite reactivation (aH) equals
the rate of new hypnozoite infection ((1-f)MS). Since treatment for blood-stage infection is rel-
atively short-lived compared to the history of infection (and has no impact on accumulated
liver stages), this should not significantly affect this steady state.
Understanding the rate of inoculation
Although we can estimate the ratio between primary infections and reactivations, we cannot di-
rectly estimate the ‘rate of infection’ (rate of new infectious inoculation from mosquito bites)
from this data. That is, for an inoculation to be infectious, it must eventually produce either
primary infection, or a hypnozoite that later reactivates. It is not clear that all inoculations
must produce a primary infection (some may produce only hypnozoites). Thus, the rate of new
primary infection in CQ+PQ individuals may or may not reflect infectious inoculation rate,
since some fraction of inoculations may produce only hypnozoites. However, the minimal rate
of infectious inoculation would occur when every new inoculation produced a primary infec-
tion. If we assume that every new inoculation must result in an early, acute blood stage infec-
tion, then the minimal inoculation rate is simply the rate of new blood stage infection in the
CQ + PQ group (and both inoculation and new primary infection would be experienced ap-
proximately every 588 days). If this were the case, it would also require that each new inocula-
tion must lay down approximately 24 hypnozoites (in order to account for the observed high
rate of hypnozoite reactivation in the CQ group)(Fig. 3B).
The alternative scenario occurs if some infectious inoculations do not produce a primary in-
fection, and instead only lay down hypnozoites. Since to be an ‘infectious inoculation’ the inoc-
ulation must produce either one primary infection or one hypnozoite, the highest rate of
infectious inoculation would be when each infection only produced exactly one infected liver
cell, which could either produce one primary infection or one hypnozoite. In this case, the rate
of infection observed in the CQ group is exactly the rate of infectious inoculation. If this were
the case, then it would require that only 4% of infectious inocula presented as a primary infec-
tion, and the rest became dormant (laid down their one hypnozoite) without being observed as
a primary infection (Fig. 3C). This seems unlikely, as there is experimental evidence that more
than one reactivation event (and thus more than one hypnozoite) can arise from a single inocu-
lation[21].
The analysis above describes the maximal and minimal rates of infectious inoculation,
which imply very different numbers of liver cells infected per inoculation. The maximal rate
suggests that 24 liver cells are infected from each infectious bite, but that this only occurs every
588 days. The minimal rate suggests that each infectious bite infects at most one liver cell, but
this happens as frequently as every 23 days. The rate of infection could also be considered in
terms of the rate of infection of liver cells (either as primary infection or hynozoites), even
without knowing how many liver cells are infected per mosquito inoculation. The infection
rate in the CQ treated group is driven by both the rate of primary infection plus the rate of hyp-
nozoite reactivation. As discussed above, the rate of reactivation reflects the sum of all previous
inoculations (at all times) and their probability of reactivating, and is thus reflective of the rate
of ‘laying down’ hypnozoites. The infection rate of the CQ group is thus the total rate of infec-
tion of liver cells (either destined for primary infection or hypnozoites), assuming that only
one cell initiates each primary infection or reactivation (assuming chloroquine is effective).
Thus, the minimum rate of liver cell infection can be derived from the CQ group, and is 0.043
infected cells per day (a new infected liver cell every 23 days). However, unless we know the
Dynamics of P. vivax Infection and Reactivation
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number of liver cells infected on each inoculation, or the proportion of inoculations that cause
primary infection, we cannot directly estimate the inoculation rate.
From the analysis above we can estimate the minimal and maximal inoculation rates, and
the minimum rate of production of new infected liver cells (which is the same as the maximal
inoculation rate). Fig. 3D illustrates one of many possible scenarios in between these extremes.
For example, if we had an infection rate of 0.0086 per day (equating to a new infection being es-
tablished every 120 days), this would require that approximately 20% of infection were ob-
served as a primary infection, and each infection produced on average five hypnozoites
(Fig. 3D). However, it is clear that although we can estimate primary infection and reactivation
rates, we cannot directly estimate the rate of infectious inoculation from the data unless we as-
sume that each infection event always produced an observed primary infection. In addition, we
cannot estimate the rate of infection of liver cells unless we assume that each infection arises
from a single infected liver cell.
Different P. vivax infection kinetics in Papua New Guinea
In order to compare these dynamics in another population, we investigated the infection rates
of patients treated with either artesunate alone, or artesunate + primaquine by analyzing a pub-
lished data set from Papua New Guinea. In order to make our analysis directly comparable
with the Thai study, we first restricted our analysis to infections detected by microscopy in the
first 60 days since treatment (Fig. 4A). In individuals receiving artesunate plus primaquine, we
observed using Equation (1) a rate of blood stage infection of 0.0102 / day (equivalent to 98
days between new blood stage infections). In individuals receiving artesunate alone, we ob-
served using Equation (2) a rate of blood stage infection of 0.0344 / day (equivalent to a new in-
fection every 29 days). Using the same approach as discussed above, we would estimate that in
Fig 4. Primaquine therapy in PNG. Fitting of the mathematical model to data from PNG. (A) The models fit (solid lines) assuming 100% efficacy of
primaquine treatment over the first 60 days after treatment is shown at left. The black line indicates the fit for the AS+PQ group, and the blue line for the AS
only group. (B) The best fit model for the full 280 day time course is shown at right, assuming that primaquine is ineffective in a proportion of individuals (B).
doi:10.1371/journal.pntd.0003595.g004
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individuals treated with artesunate alone, 30% of infections occur due to primary infection and
70% due to hypnozoites reactivation (a ratio of 2.37 to 1). This ratio of reactivation to primary
infection is 10 fold lower than the ratio observed in the Thai study. There was no evidence for a
significant difference in the estimated delays to first detection of infection in AS+PQ group
and AS only groups (p = 0.0807, F-test). The large difference in the ratio of primary infection
to hypnozoite reactivation between the Thai and PNG studies raises a number of questions,
which we explore below.
Modeling the impact of drug efficacy on infection
One reason for the difference between the Thai and PNG studies could arise from primaquine
resistance. That is, either particular strains of parasites or particular individuals may be resis-
tant to primaquine. If primaquine were only effective in a subset of parasite strains, then only a
fraction of hypnozoites (from sensitive strains) would be killed by treatment. Hypnozoite reac-
tivation would then be reduced by this fraction, and we would see simply an increase in the (ex-
ponential) rate of infection in the primaquine treated group. Alternatively, if primaquine was
only effective in a proportion of individuals, then we might expect to see a rapid rate of infec-
tion in primaquine-resistant individuals (at the same rate as those receiving artesunate alone,
due to both primary infection and hypnozoite reactivation), and a slow rate of primary infec-
tion in those in whom primaquine was effective. This would produce a different (non-expo-
nential) infection curve, characterized by two populations and two infection rates.
In order to assess whether primaquine resistance might either affect a proportion of strains,
or a proportion of individuals, we modeled the full time course of infection in the PNG data
(comparing Equations (1), (2) and (4)). We found that a model in which a proportion of indi-
viduals are primaquine-resistant (Equation 4) provides a significantly better fit to the data
(p<0.0001, F-test). In the case of primaquine resistant individuals, the infection rate in those in
whom primaquine was ineffective should be the same as the infection rate in those receiving
artesunate alone, and we can estimate the rate for those with successful primaquine therapy in-
dependently. When we fit the data to this function (Equation 4), we can estimate that the best
fit to the data occurs if primaquine is effective in60% percent of individuals, and the rate of
primary infection (in the group in which primaquine was effective) was 0.0032 / day (equiva-
lent to a new primary infection every 313 days). Interestingly, this gives a ratio of primary in-
fection to reactivation of 1 to 9, which is much more similar to the rate estimated from the
Thai study. Table 1 shows the best-fit estimates of the models (1), (2) and (4) to the both Thai
and PNG data sets.
Modeling primary infection and reactivation with P. vivax
A second difference between the Thai and PNG studies is the age of the cohorts, which was
young in PNG, but included all ages in Thailand. Therefore we asked whether age may affect
the proportion of infections arising from hypnozoite reactivation. Primary infection arises
soon after infectious inoculation, and thus should be proportional to the current rate of infec-
tious inoculation. By contrast, reactivation from hypnozoites requires first the establishment of
a ‘reservoir’ of hypnozoites from previous infections, and then their later reactivation. Thus,
for example, after the first exposure in life, only hynozoites laid down by the first inoculation
can reactivate. However, after many exposures, reactivation can occur from hynozoites laid
down at different times in the past. This is evident from previous studies of P. vivax clonotypes
in infection. These studies have analysed the relationship between P. vivax clonotypes from
baseline infection, and in subsequent infectious episodes. In adults, these clonotypes are very
often unrelated, consistent with reactivation of hypnozoites laid down prior to the most recent
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infection event [13, 14, 22]. However, in children it is more likely that baseline infection and
subsequent reactivation will be due to the same clonotype [23].
We modeled the rates of primary infection and reactivation with age, to investigate how this
might impact our analysis (using Equations (5), (6) and (7). The results suggest that for a given
infection rate, the rate of primary infection is constant over time, but the rate of reactivation
takes some time to reach its long-term level. Therefore at young ages we would expect an over-
all lower rate of infection (due to a lower rate of hypnozoite reactivation), as well as a higher
ratio of primary infection to reactivation. How long this effect would be observed is directly re-
lated to the average time between laying down of hypnozoites and their subsequent reactivation
(as shown in Fig. 5A). However, since the average time for hypnozoites to reactivate is thought
to be of the order of months in tropical regions, this effect should only be present very early
after initial exposure, and seems unlikely to have been the cause of the observed differences be-
tween the PNG and Thai cohorts.
The analysis above suggest that if age plays an important role in the ratio of primary infec-
tion to reactivation, then younger children treated with CQ in the Thai cohort should also ex-
hibit an overall lower infection rate than older individuals (because of the reduced rate of
hypnozoite reactivation). To test this we analysed the rate of infection of the children aged<5
years in the CQ treated cohort from the Thai study. Our fitting using Equation (2) showed no
evidence for a significant difference in the rate of infection between those aged< 5 years or>5
Table 1. The best-fit parameters estimate for the contribution of new infection to dormant-liver stage
activation.
Thai Data
Parameters Infection rate (blood stage
infections/day) (95% CI)
Average time between
infections (Days) (95% CI)
Infection rate in CQ+PQ treated
group (k). (Equation 1)
0.0017 (0.0006, 0.0027) 588 (370, 806)
Infection rate in CQ treated group
(k(1+c)). (Equation 2)
0.0430 (0.0163, 0.0697) 23 (14, 32)
Ratio of relapse to reinfection (c) 24.3 (8.56, 40.0)
% infections due to hypnozoite
reactivation.
96% (90%, 98%)
PNG Data (assuming 100% drug efficacy, first 60 days)
Infection rate in AS+PQ group (k).
(Equation 1)
0.0102 (0.0085, 0.0120) 98 (83,113)
Infection rate in AS group (k(1
+c)). (Equation 2)
0.0344 (0.0275, 0.0413) 29 (24,34)
Ratio of relapse to reinfection (c) 2.37 (1.69, 3.05)
% infections due to hypnozoite
reactivation.
70.3% (63%, 75%)
PNG Data (Estimating drug resistance, full Time Course)
Infection rate in AS+PQ group
(Equation 4).
0.0032 (0.0023, 0.0041) 312 (243, 381)
Infection rate in AS group (k(1
+c)). (Equation 2)
0.0325 (0.0232, 0.0418) 31 (24,38)
Ratio of relapse to reinfection (c) 9.16 (6.25, 12.06)
% infections due to hypnozoite
reactivation.
90%(86%, 92%)
Estimated treatment failure rate 40% (32%, 48%)
doi:10.1371/journal.pntd.0003595.t001
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years old in the Thai cohort (p = 0.2493, F-test, Fig. 5B). Thus, it seems unlikely that age alone
would explain the difference between the Thai and PNG studies.
The model above considers how the infection rate from new inoculation and reactivation of
P. vivax hypnozoites evolves with age in children exposed to infection. The same dynamics of
accumulation of hypnozoites will also occur after successful primaquine therapy, when again
the individual starts with no hypnozoite reservoir. After successful primaquine therapy both
the number of hypnozoites and the rate of infection from hypnozoites will similarly increase
over time.
Understanding the effects of infection rate and seasonality
Other mechanisms for the differences between the Thai and PNG studies include the overall
rate of inoculation, as well as seasonal fluctuations in this. Changes in the inoculation rate per
se should not affect the ratio of primary infection to reactivation. That is, the average ratio of
primary infection to reactivation is determined by the proportion of sporozoites progressing
immediately to infection versus becoming hypnozoites, and is relatively independent of the
rate of inoculation. Moreover, comparing the groups with treatment for blood stage infection
only (CQ in Thailand and AS in PNG), the rate of infection in these groups was similar (0.043
vs. 0.034 infections per day, respectively). Once we accounted for treatment resistance, our esti-
mated rate of new primary infection was also similar (0.0017 vs. 0.0032 per day, respectively).
Thus, it seems unlikely that differences in the rate of infection were a major factor.
Seasonal fluctuations in the rate of new infections will have a direct effect on the rate of pri-
mary infection over time. However, if the reactivation of hypnozoites happens on a longer
timescale, it may be less susceptible to seasonal variation, and thus alter the ratio of primary in-
fection to hypnozoite reactivation over the seasons. Since the PNG study may have a higher de-
gree of seasonality compared with the Thai study [8, 9], we explored the predicted impact of
seasonality. We modeled a sinusoidal variation in the rate of overall infection (Equation (9)),
and a constant fraction of infections becoming primary infection (Equation (5) or being laid
down as hypnozoites (Equation (6)) and later reactivating (Equation (7)). The rate of infection
from primary infection and hypnozoite reactivation thus evolve over time as described in
Fig 5. Dynamics of P. vivax infection with time. (A) Modeling the proportion of infections from new primary infection versus hypnozoite reactivation with
time. In the presence of a constant rate of inoculation, the rate of primary infection (black line) will rapidly reach equilibrium and be constant with time.
However, the rate of hypnozoite reactivation (blue line) will take some time to reach its steady state level. The time taken to reach this is dependent on the
rate of reactivation of hypnozoites (aH). (B) shows best-fits of time to Pv infection in children< 5 years or subjects>5 years old in the Thai study.
doi:10.1371/journal.pntd.0003595.g005
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Equations (5) and (8) respectively. When the average time to hypnozoite reactivation was short
(one month, Fig. 6A), the number of hypnozoites and rate of hypnozoite reactivation fluctuates
a lot over time, mirroring (with slight delay) the fluctuations in primary infection. However, as
the average time to hypnozoite reactivation gets longer (Fig. 6B and 6C)), the number of hyp-
nozoites and rate of hypnozoite reactivation becomes less variable with season. For our pur-
poses, we are most interested in how seasonal fluctuation in infection rate might affect the ratio
of primary infection to hypnozoite reactivation. Somewhat counter-intuitively, the shorter the
time to hypnozoite reactivation, the less seasonal fluctuation in this ratio is seen (Fig. 6D).
Thus, seasonality of infection may significantly alter the ratio, but this is least likely to have an
effect with tropical strains of P. vivax, where the time to hypnozoite reactivation is thought to
be relatively short. In our modeling, the rate of hypnozoite reactivation was assumed to be in-
dependent of season. However some have suggested that there may be a seasonality in presen-
tation from UK residents returning from endemic regions[24], supporting a varying
reactivation rate with season, which could further affect the ratio of primary infections
to reactivation.
Fig 6. Impact of seasonality in transmission. (A–C) The rate of primary infection over time (black line) and hypnozoite reactivation with time (coloured
lines) with seasonal transmission is plotted for different rates of hypnozoite reactivation. Rapid hypnozoite reactivation (half-life of one month) leads to rapid
fluctuation in the rate of infection from hypnozoite reactivation. Slower rates of reactivation, equivalent of a half-life of six months (B) or 12 months (C) lead to
more stable levels of hypnozoite reactivation. (D), The effect of seasonality on the ratio of hypnozoite reactivation versus primary infection when reactivation
is of order of a month (red line), order of six months (green line) and order of a year (blue line). The ratio of infections from hypnozoite reactivation versus
primary infection is paradoxically more stable in the setting of rapid hypnozoite reactivation (red line).
doi:10.1371/journal.pntd.0003595.g006
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Discussion
In the study we have estimated the relative contribution of new primary infection and the reac-
tivation of dormant liver-stage hypnozoites to the rate of blood stage infection in individuals
living in the P. vivax endemic areas. Our modeling results showed that the vast majority of in-
fections (96%) in Thailand were due to hypnozoite reactivation. The proportion of infection
due to hypnozoite reactivation in PNG was less clear. Considering only the early phase of infec-
tion and 100% efficacy of primaquine, we would estimate that only 70% of infections in PNG
were due to hypnozoite reactivation. However, we found that when the full time course of in-
fection was considered, we had a significantly better fit to a model in which up to 40% of PNG
individuals were resistant to primaquine therapy. If this level of primaquine resistance in the
population is correct, then 90% of the infections were due to hypnozoite reactivation in the
PNG cohort study.
A number of factors differed between the Thai and PNG studies that might affect our re-
sults. Firstly, the age of the cohorts was different, with the PNG cohort focused on children 1–5
years of age, whereas the Thai cohort included individuals of all ages. Age may play a role in
susceptibility to P. vivax infection [25, 26], and in the ratio of primary infection to reactivation.
However, if we restricted our analysis to the 1–5 years age group in the Thai study, we found a
similar overall infection rate to the rest of the cohort. Secondly, there may have been differences
in the infection rate or seasonality of infection between the studies. However, again we found
that these were unlikely to have a profound effect on the ratio of primary infection to reactiva-
tion. Since the drug dosage differed between PNG and Thailand, this may have contributed to
treatment failure. However, since the dose of primaquine given was higher in the PNG study
(0.5 mg/kg in PNG vs 0.25 mg/kg in Thailand), this would not appear to support less effective
treatment in PNG. Finally, it has been suggested that P. falciparum infection may precipitate P.
vivax hypnozoite reactivation [27, 28]. In the Thai cohort, patients who had mixed infection at
enrolment were excluded. However, in the PNG cohort these patients were included. Thus, if
recent infection with P. falciparum precipitates P. vivax reactivation, this may have driven ear-
lier reactivation in some patients the PNG study. As we do not have data on which patients
were co-infected at enrolment in this cohort, we are unable to exclude this as a factor in
our study.
In our analysis of primary infection and reactivation, we first assumed a constant ‘force of
infection’. That is, we assumed that the rate of infectious inoculation, new primary infection,
and reactivation of hypnozoites was relatively constant over the period of study. While the as-
sumption of stable infection rate is easy to understand, the assumption of a constant rate of re-
activation is less clear. That is, one might expect that following a single infection event,
hypnozoites may be more likely to activate early than late, and therefore we might see a de-
crease in hypnozoite reactivation rate over time [19]. However, we show that since individuals
are presumed exposed to the same rate of inoculation before and after therapy, they will be in a
‘steady state’ in which, regardless of the distribution of times for hypnozoites to reactivate, the
observed rate of infection from hypnozoite reactivation is effectively constant with time. Ex-
ploring the impact of seasonal variations in infection rate, we find that these can significantly
affect the ratio of primary infection to reactivation over time.
Our studies indicated that the infection dynamics of the AS + PQ group in PNG could be
best fit by assuming that primaquine was ineffective in a proportion of individuals in the PNG
study. This not only provided a significantly better fit to the shape of the AS+PQ reinfection
curves, but also led to a ratio of primary infection too reactivation that was much more similar
to the Thai study. Here, it is important to differentiate parasite resistance to primaquine from
ineffectiveness of primaquine in a given host. The former would result in the clearance of only
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a proportion of [susceptible] hypnozoites, whereas the latter would lead to clearance of all hyp-
nozoites in a proportion of individuals. The possibility of true primaquine resistance is ques-
tioned by some, who suggest that variation in host genetics may lead to ineffectiveness of
primaquine in a subset of individuals [29]. Primaquine is not itself active, and requires metabo-
lism by cytochrome P450 isoenzymes to its active form [30]. Human populations vary in the
proportion of functional and non-functional CYP2D6 alleles, with PNG having a high propor-
tion of novel and uncharacterized alleles [31]. Although these novel alleles have not been bio-
chemically characterized, many are assumed to be active [32]. In addition, there appears
evidence that parasites acquired in PNG are less susceptible to primaquine. Thus, it seems
highly likely that treatment failure is indeed higher in PNG.
Understanding the relative contribution of primary infection and relapse in P. vivax infec-
tion is important to driving future treatment strategies. We have developed a novel analytical
framework that allows estimation of the primary infection to reactivation ratio. This work indi-
cates that reactivation of hypnozoites contributes 90–96% of observed P. vivax infections. In
addition, our work suggests approaches for understanding the level of primaquine resistance in
different populations. Understanding the mechanism of hypnozoite reactivation and identify-
ing optimal approaches for targeting the hypnozoite reservoir will greatly reduce the burden of
P. vivax infection.
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